Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial.

Authors

Julie Nicole Graff

OHSU Knight Cancer Institute, Portland VA Medical Center, Portland, OR

Julie Nicole Graff , Giulia Baciarello , Andrew J. Armstrong , Celestia S. Higano , Peter Iversen , David Forer , Harry H. Mansbach , De Phung , Bertrand F. TOMBAL , Tomasz M. Beer , Cora N. Sternberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01212991

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 200)

DOI

10.1200/jco.2015.33.7_suppl.200

Abstract #

200

Poster Bd #

J10

Abstract Disclosures

FEATURED

Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial.

Authors

Julie Nicole Graff

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.